Affordable Access

deepdyve-link
Publisher Website

Comparing and Contrasting MERS, SARS-CoV, and SARS-CoV-2: Prevention, Transmission, Management, and Vaccine Development.

Authors
  • Oves, Mohammad1
  • Ravindran, Mithunan2, 3
  • Rauf, Mohd Ahmar4
  • Omaish Ansari, Mohammad5
  • Zahin, Maryam6
  • Iyer, Arun K4
  • Ismail, Iqbal M I1, 7
  • Khan, Meraj A2, 8
  • Palaniyar, Nades2, 3, 8
  • 1 Centre of Excellence in Environmental Studies, King Abdulaziz University, Jeddah, Makkah 21589, Saudi Arabia. , (Saudi Arabia)
  • 2 Program in Translational Medicine, SickKids Research Institute, The Hospital for Sick Children, Toronto, ON M5G 1X8, Canada. , (Canada)
  • 3 Faculty of Medicine, University of Toronto, Toronto, ON M5S1A8, Canada. , (Canada)
  • 4 Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA.
  • 5 Center of Nanotechnology, King Abdulaziz University, Jeddah, Makkah 21589, Saudi Arabia. , (Saudi Arabia)
  • 6 Center for Predictive Medicine and James Graham Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
  • 7 Department of Chemistry, Faculty of Science, King Abdulaziz University, Jeddah, Makkah 21589, Saudi Arabia. , (Saudi Arabia)
  • 8 Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, ON M5S1A8, Canada. , (Canada)
Type
Published Article
Journal
Pathogens (Basel, Switzerland)
Publication Date
Nov 26, 2020
Volume
9
Issue
12
Identifiers
DOI: 10.3390/pathogens9120985
PMID: 33255989
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The COVID-19 pandemic is responsible for an unprecedented disruption to the healthcare systems and economies of countries around the world. Developing novel therapeutics and a vaccine against SARS-CoV-2 requires an understanding of the similarities and differences between the various human coronaviruses with regards to their phylogenic relationships, transmission, and management. Phylogenetic analysis indicates that humans were first infected with SARS-CoV-2 in late 2019 and the virus rapidly spread from the outbreak epicenter in Wuhan, China to various parts of the world. Multiple variants of SARS-CoV-2 have now been identified in particular regions. It is apparent that MERS, SARS-CoV, and SARS-CoV-2 present with several common symptoms including fever, cough, and dyspnea in mild cases, but can also progress to pneumonia and acute respiratory distress syndrome. Understanding the molecular steps leading to SARS-CoV-2 entry into cells and the viral replication cycle can illuminate crucial targets for testing several potential therapeutics. Genomic and structural details of SARS-CoV-2 and previous attempts to generate vaccines against SARS-CoV and MERS have provided vaccine targets to manage future outbreaks more effectively. The coordinated global response against this emerging infectious disease is unique and has helped address the need for urgent therapeutics and vaccines in a remarkably short time.

Report this publication

Statistics

Seen <100 times